Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Theseus Pharmaceuticals (THRX)
NASDAQ:THRX
RESEARCH TOOLSreports
Holding THRX?
Track your performance easily
THRX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.05 - $12.37
Previous Close$4.06
Volume3.12M
Average Volume (3M)489.12K
Market Cap
$179.57M
Enterprise Value-$21.89M
Total Cash (Recent Filing)$205.12M
Total Debt (Recent Filing)$3.66M
Price to Earnings (P/E)―
Beta2.22
Next Earnings
Mar 07, 2024EPS Estimate
-$0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.34
Shares Outstanding44,230,135
10 Day Avg. Volume195,048
30 Day Avg. Volume489,120
Standard Deviation0.46
R-Squared0.25
Alpha0.00656
Financial Highlights & Ratios
Price to Book (P/B)0.75
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.49
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
Theseus Pharmaceuticals News
PremiumCompany Announcements
Theseus Pharmaceuticals’ Strategic Merger and Corporate Restructuring
Ownership Overview
11.99% Insiders
7.24% Mutual Funds
73.10% Other Institutional Investors
7.68% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
THRX FAQ
What was Theseus Pharmaceuticals’s price range in the past 12 months?
Theseus Pharmaceuticals lowest stock price was $2.05 and its highest was $12.37 in the past 12 months.
What is Theseus Pharmaceuticals’s market cap?
Currently, no data Available
When is Theseus Pharmaceuticals’s upcoming earnings report date?
Theseus Pharmaceuticals’s upcoming earnings report date is Mar 07, 2024 which is 288 days ago.
How were Theseus Pharmaceuticals’s earnings last quarter?
Theseus Pharmaceuticals released its earnings results on Nov 13, 2023. The company reported -$0.325 earnings per share for the quarter, beating the consensus estimate of -$0.36 by $0.035.
Is Theseus Pharmaceuticals overvalued?
According to Wall Street analysts Theseus Pharmaceuticals’s price is currently Overvalued.
Does Theseus Pharmaceuticals pay dividends?
Theseus Pharmaceuticals does not currently pay dividends.
What is Theseus Pharmaceuticals’s EPS estimate?
Theseus Pharmaceuticals’s EPS estimate is -$0.29.
How many shares outstanding does Theseus Pharmaceuticals have?
Theseus Pharmaceuticals has 44,230,000 shares outstanding.
What happened to Theseus Pharmaceuticals’s price movement after its last earnings report?
Theseus Pharmaceuticals reported an EPS of -$0.325 in its last earnings report, beating expectations of -$0.36. Following the earnings report the stock price went up 0.943%.
Which hedge fund is a major shareholder of Theseus Pharmaceuticals?
Among the largest hedge funds holding Theseus Pharmaceuticals’s share is Omega Fund Management, LLC. It holds Theseus Pharmaceuticals’s shares valued at 3M.
---
Theseus Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
― (―)
― (―)
Blogger Sentiment
Bullish
THRX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 384.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 11.7%
Last 30 Days ▼ 16.0%
Last 30 Days ▼ 16.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-58.52%
12-Months-Change
Fundamentals
Return on Equity
-25.55%
Trailing 12-Months
Asset Growth
1.88%
Trailing 12-Months
Company Description
Theseus Pharmaceuticals
Theseus Pharmaceuticals Inc is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. The company's development programs are designed to address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer.
---
THRX Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Best Analysts Covering THRX
1 Year
1 Year Success Rate
3/7 ratings generated profit
1 Year Average Return
-9.74%
reiterated a buy rating a year ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 42.86% of your transactions generating a profit, with an average return of -9.74% per trade.
---